of considering non-pharmacological treatments for insomnia disorder, as they are supported by high-
quality evidence and recommended as first-line treatment by guidelines [Riemann et al., 2017].
In a 2017 Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia in adults by
the American Academy of Sleep Medicine, melatonin is recommended against for the treatment of sleep
onset or sleep maintenance insomnia [Sateia et al., 2017]. For sleep onset insomnia, eszopiclone,
zaleplon, zolpidem, triazolam, and ramelteon are recommended. For sleep maintenance insomnia,
suvorexant, zolpidem, temazepam, and doxepin are recommended. However, all of these
recommendations are weak recommendations (based on the GRADE process) reflecting a lower degree
of certainty in the outcome and appropriateness of the patient-care strategy for all patients.
Delirium: MAY DECREASE DELIRIUM INCIDENCE AND DURATION BUT FINDINGS ARE MIXED
Delirium is characterized by disturbance in attention, awareness, and cognition. Delirium is a common
complication in hospitalized patients, especially in older patients, and it is associated with a longer
hospital stay, increased risk of functional and cognitive decline, increased dementia risk, and increased
mortality risk [Pereira et al., 2021; Inouye et al., 2023]. Other predisposing factors of delirium include
medical comorbidities (e.g., pre-existing cognitive impairment, atherosclerosis, etc.), medication use,
intraoperative factors (e.g., use of benzodiazepines, highly invasive surgery), postoperative factors (e.g.,
pain), and circadian rhythm disturbance [Barnes et al., 2023]. Sleep deprivation and delirium share
behavioral and biological similarities, including disturbances in the sleep-wake cycle and abnormal
melatonin secretion [Weinhouse et al., 2009; Yoshitaka et al., 2013]. Observational studies have
reported lower plasma melatonin levels in people with delirium compared to those without delirium
[Yoshitaka et al., 2013]. While the causes of delirium are not clearly defined and likely vary across
people, several potential causes are modulated by melatonin, including diurnal sleep disturbance,
melatonin dysregulation, neuroinflammation, oxidative stress, and neurotransmitter dysregulation
[Maldonado, 2013].
In a 2023 meta-analysis of 8 randomized controlled trials in ICU patients, melatonin treatment did not
significantly reduce delirium incidence (RR=0.76; 95% CI, 0.54 to 1.07; p=0.12), based on 6 randomized
controlled trials that included a total of 1,625 patients [Aiello et al., 2023]. However, a sensitivity
analysis that added 4 studies (2 retrospective studies and 2 randomized controlled trials) showed that
melatonin/ramelteon reduced delirium risk (RR=0.67; 95% CI, 0.48 to 0.92; p=0.01). Of secondary
outcomes, there was a trend towards a reduction in the duration of mechanical ventilation (mean
difference, -2.80; p=0.09), but no significant effects in the ICU length of stay (mean difference, -0.26;